Clinical Trial: Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)

Study Status: Recruiting
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)

Brief Summary:

Present imaging modalities for primary liver cancer (hepatocellular carcinoma or HCC) have several shortcomings. One important shortcoming is the time delay between successful treatment and radiological confirmation of this response. Often it takes several months for anatomical changes to occur and to be appreciated on morphological imaging such as CT or MRI (shrinkage of tumor, absence of contrast enhancement). Functional imaging by means of Fluor-18 deoxyglucose or Fluor-18 Choline (positron emitters, PET-scan) might be an early indicator of response. This "early" information might help to tailor treatment. For instance, if no response is induced, an early switch in therapy can be planned.

The present study investigates whether the routine PET-tracer (Fluor-18 deoxyglucose) and the experimental PET-tracer, Fluor-18 Choline help to predict response if a patient with inoperable primary liver cancer is treated (radionuclide therapy, biologicals).

Detailed Summary:
Sponsor: University Hospital, Ghent

Current Primary Outcome: To evaluate the efficacy of PET-imaging versus classic response assessment (MRI, CT-scam) in patients with inoperable liver cancer [ Time Frame: 6 months after start of treatment ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University Hospital, Ghent

Dates:
Date Received: May 3, 2010
Date Started: May 2010
Date Completion: October 2015
Last Updated: December 4, 2014
Last Verified: December 2014